by Richard Daverman, PhD
September 25, 2012 -- BGI, the genomics powerhouse headquartered in Shenzhen, will build a next generation sequencing facility in Singapore as part of a partnership with INEX Innovations Exchange, a Singapore-based women’s health diagnostics company. BGI has developed a non-invasive test that uses a blood sample from a pregnant mother to screen for three chromosomal abnormalities in the fetus. One of the abnormalities results in Down Syndrome. The test replaces an amniocentesis procedure, which has a 1% chance of causing a miscarriage. More details....
